Annual report pursuant to Section 13 and 15(d)

Stockholders' (Deficiency) Equity (Tables)

v3.24.1.1.u2
Stockholders' (Deficiency) Equity (Tables)
12 Months Ended
Mar. 31, 2022
Stockholders' (Deficiency) Equity  
Summary of stock-based compensation expense by statement of operations line item

The following table summarizes, by consolidated statements of operations line item, stock-based compensation expense (in thousands):

Year Ended March 31,

2022

    

2021

    

(Restated)

    

(Restated)

 

Cost of goods sold

$

109

    

$

83

Research and development

 

79

 

41

Selling, general and administrative

 

1,057

 

813

Stock-based compensation expense

$

1,245

$

937

Summary of stock option activity

Weighted

Average Grant

Date Fair

Restricted Stock Units and Performance Restricted Stock Units

Shares

Value

 

Non-vested restricted stock units outstanding at March 31, 2021

    

497,281

    

$

5.65

Granted

 

328,963

5.40

Vested and issued

 

(194,444)

5.18

Forfeited

 

(39,995)

5.78

Non-vested restricted stock units outstanding at March 31, 2022

 

591,805

5.66

Restricted stock units expected to vest beyond March 31, 2022

 

591,805

$

5.66

Summary of restricted stock activity

The following table provides additional information on restricted stock units and performance restricted stock units:

Year Ended March 31,

2022

    

2021

    

    

(Restated)

    

(Restated)

Restricted stock compensation expense (in thousands)

    

$

1,245

    

$

937

Aggregate fair value of restricted stock units vested and issued (in thousands)

    

$

936

    

$

352

Weighted average grant date fair value of restricted stock units granted during the period

    

$

5.40

    

$

5.28

Schedule of fair value assumptions - warrants

Risk-free interest rate

 

0.2%

Contractual term

 

3 years

Expected volatility

 

81.0%